A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer

PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abirat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: McKay, Rana R., Werner, Lillian, Mostaghel, Elahe A., Lis, Rosina, Voznesensky, Olga, Zhang, Zhenwei, Marck, Brett T., Matsumoto, Alvin M., Domachevsky, Liran, Zukotynski, Katherine A., Bhasin, Manoj, Bubley, Glenn J., Montgomery, Bruce, Kantoff, Philip W., Balk, Steven P., Taplin, Mary-Ellen
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315609/
https://ncbi.nlm.nih.gov/pubmed/27683182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0987
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires